Cargando…

CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma

BACKGROUND: Cardiotrophin-like cytokine factor 1 (CLCF1) has been described as an oncogene and a potential therapeutic target in a variety of cancers, but its role in glioma remains unknown. METHODS: Based on The Cancer Genome Atlas (TCGA), we conducted a bioinformatics analysis to investigate the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yuan, Ji, Qiankun, Long, Xiaoyan, Wang, Peng, Tu, Zewei, Zhang, Xian, Zhu, Xingen, Huang, Kai, Li, Jingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898905/
https://www.ncbi.nlm.nih.gov/pubmed/35265072
http://dx.doi.org/10.3389/fimmu.2022.810832
_version_ 1784663777823686656
author Jiang, Yuan
Ji, Qiankun
Long, Xiaoyan
Wang, Peng
Tu, Zewei
Zhang, Xian
Zhu, Xingen
Huang, Kai
Li, Jingying
author_facet Jiang, Yuan
Ji, Qiankun
Long, Xiaoyan
Wang, Peng
Tu, Zewei
Zhang, Xian
Zhu, Xingen
Huang, Kai
Li, Jingying
author_sort Jiang, Yuan
collection PubMed
description BACKGROUND: Cardiotrophin-like cytokine factor 1 (CLCF1) has been described as an oncogene and a potential therapeutic target in a variety of cancers, but its role in glioma remains unknown. METHODS: Based on The Cancer Genome Atlas (TCGA), we conducted a bioinformatics analysis to investigate the clinical significance and biological functions of CLCF1 in glioma at the transcriptional level and predicted the response to immunotherapy of glioma patients with different CLCF1 expression levels. All the results were further verified in Chinese Glioma Genome Altas(CGGA) Data processing and figure generating were performed with R language. RESULTS: Elevated CLCF1 expression was common in cancers and usually predicted poor prognosis, which was also consistent with gliomas. In Univariate Cox Regression analysis and Kaplan-Meier survival analysis, tumor patients with higher CLCF1 expression tended to experience a worse prognosis. In the multivariate Cox proportional hazard model, the expression of CLCF1 was an independent prognostic factor in gliomas. The biological function analysis of CLCF1 in glioma showed that CLCF1 was closely associated with immune signatures, including immune-related pathways, immune cell infiltration, and immune checkpoints. Moreover, glioma patients with low CLCF1 expression showed a greater tendency to respond to anti-PD1/PD-L1 immunotherapy, indicating CLCF1 also had potential clinical significance in guiding immunotherapy. And CLCF1 as a member of the IL6 family had a better predictive value for prognosis and immunotherapy response in glioma than that of IL6 and other IL6 family members. CONCLUSION: CLCF1 expression is an independent prognosticator and a promising therapeutic target correlated with immunotherapy in glioma.
format Online
Article
Text
id pubmed-8898905
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88989052022-03-08 CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma Jiang, Yuan Ji, Qiankun Long, Xiaoyan Wang, Peng Tu, Zewei Zhang, Xian Zhu, Xingen Huang, Kai Li, Jingying Front Immunol Immunology BACKGROUND: Cardiotrophin-like cytokine factor 1 (CLCF1) has been described as an oncogene and a potential therapeutic target in a variety of cancers, but its role in glioma remains unknown. METHODS: Based on The Cancer Genome Atlas (TCGA), we conducted a bioinformatics analysis to investigate the clinical significance and biological functions of CLCF1 in glioma at the transcriptional level and predicted the response to immunotherapy of glioma patients with different CLCF1 expression levels. All the results were further verified in Chinese Glioma Genome Altas(CGGA) Data processing and figure generating were performed with R language. RESULTS: Elevated CLCF1 expression was common in cancers and usually predicted poor prognosis, which was also consistent with gliomas. In Univariate Cox Regression analysis and Kaplan-Meier survival analysis, tumor patients with higher CLCF1 expression tended to experience a worse prognosis. In the multivariate Cox proportional hazard model, the expression of CLCF1 was an independent prognostic factor in gliomas. The biological function analysis of CLCF1 in glioma showed that CLCF1 was closely associated with immune signatures, including immune-related pathways, immune cell infiltration, and immune checkpoints. Moreover, glioma patients with low CLCF1 expression showed a greater tendency to respond to anti-PD1/PD-L1 immunotherapy, indicating CLCF1 also had potential clinical significance in guiding immunotherapy. And CLCF1 as a member of the IL6 family had a better predictive value for prognosis and immunotherapy response in glioma than that of IL6 and other IL6 family members. CONCLUSION: CLCF1 expression is an independent prognosticator and a promising therapeutic target correlated with immunotherapy in glioma. Frontiers Media S.A. 2022-02-21 /pmc/articles/PMC8898905/ /pubmed/35265072 http://dx.doi.org/10.3389/fimmu.2022.810832 Text en Copyright © 2022 Jiang, Ji, Long, Wang, Tu, Zhang, Zhu, Huang and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Jiang, Yuan
Ji, Qiankun
Long, Xiaoyan
Wang, Peng
Tu, Zewei
Zhang, Xian
Zhu, Xingen
Huang, Kai
Li, Jingying
CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma
title CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma
title_full CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma
title_fullStr CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma
title_full_unstemmed CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma
title_short CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma
title_sort clcf1 is a novel potential immune-related target with predictive value for prognosis and immunotherapy response in glioma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898905/
https://www.ncbi.nlm.nih.gov/pubmed/35265072
http://dx.doi.org/10.3389/fimmu.2022.810832
work_keys_str_mv AT jiangyuan clcf1isanovelpotentialimmunerelatedtargetwithpredictivevalueforprognosisandimmunotherapyresponseinglioma
AT jiqiankun clcf1isanovelpotentialimmunerelatedtargetwithpredictivevalueforprognosisandimmunotherapyresponseinglioma
AT longxiaoyan clcf1isanovelpotentialimmunerelatedtargetwithpredictivevalueforprognosisandimmunotherapyresponseinglioma
AT wangpeng clcf1isanovelpotentialimmunerelatedtargetwithpredictivevalueforprognosisandimmunotherapyresponseinglioma
AT tuzewei clcf1isanovelpotentialimmunerelatedtargetwithpredictivevalueforprognosisandimmunotherapyresponseinglioma
AT zhangxian clcf1isanovelpotentialimmunerelatedtargetwithpredictivevalueforprognosisandimmunotherapyresponseinglioma
AT zhuxingen clcf1isanovelpotentialimmunerelatedtargetwithpredictivevalueforprognosisandimmunotherapyresponseinglioma
AT huangkai clcf1isanovelpotentialimmunerelatedtargetwithpredictivevalueforprognosisandimmunotherapyresponseinglioma
AT lijingying clcf1isanovelpotentialimmunerelatedtargetwithpredictivevalueforprognosisandimmunotherapyresponseinglioma